CoChat
Sign Up
Cited by 90Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchViral Infections and Immunology Research

Herpes Zoster: Diagnostic, Therapeutic, and Preventive Approaches

Bader, Mazen S.·2013·Postgraduate Medicine
DOI 10.3810/pgm.2013.09.2703
Open this paper in CoChat — free account

Abstract

Herpes zoster (Hz), which generally presents as a localized, painful cutaneous eruption, is a common clinical problem, particularly among adults ≥ 50 years of age and immunocompromised patients. The diagnosis of Hz is mainly made clinically, except in patients with atypical manifestations or certain complications, such as central nervous system involvement, in which laboratory virologic testing is required. In addition to having a higher mortality rate, immunocompromised individuals have atypical and severe clinical findings and are at greater risk for complications and recurrence of Hz. Treatment of Hz includes the use of antiviral agents, analgesics for control of acute zoster pain, good skin care for healing, and prevention of secondary bacterial infection. Antiviral agents, preferably valacyclovir or famciclovir, should be started within 72 hours of onset to reduce the severity of the infection, the duration of the eruptive phase, and the intensity of acute pain. Herpes zoster has been associated with several complications, of which post-herpetic neuralgia (PHN) is the most common and debilitating. Varicella-zoster virus vaccine and early treatment with either famciclovir or valacyclovir are the only measures proven to prevent PHN. The options for treating PHN include topical agents, such as lidocaine patches, and systemic agents, such as the anticonvulsants gabapentin and pregabalin. Measures for preventing Hz include infection control through routine hand hygiene and appropriate use of isolation precautions and personal protective equipment; immunoglobulins, such as the varicella-zoster virus immunoglobulin and vaccine; and antiviral agents. The zoster vaccine has been shown to be effective in reducing the incidence of Hz and PHN. The vaccine is recommended for all individuals aged ≥ 60 years who have no contraindications, including individuals who report a previous episode of Hz.

Integrity signals

Registry

Crossref · 10.3810/pgm.2013.09.2703

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • An increased risk of herpes zoster infection has been found in these individuals and administration of prophylaxis is recommended for patients at risk.

    “An increased risk of herpes zoster infection has been found in those individuals and administration of prophylaxis is recommended for patients at risk 174 .”

    From Osteosarcoma (2022) · cites this paper as [174]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Bader, M. S.
Affiliations
Juravinski Cancer Centre (CA)
Corresponding author
Bader, Mazen S.
Venue
Postgraduate Medicine
Publisher
Informa UK Limited
Published
2013-09
Volume
125
Issue
5
Pages
78-91
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
DOI
10.3810/pgm.2013.09.2703
OpenAlex
W2051875282
Cited by
90
References
114
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 10 · 2022: 11 · 2021: 7 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 5 · 2015: 8 · 2014: 1
FWCI
3.37
Type
journal article
Language
en
Open access
closed
Locations
  • Postgraduate Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Herpesvirus Infections and Treatments
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Viral Infections and Immunology Research
Keywords
herpes zoster, varicella-zoster virus, postherpetic neuralgia, antiviral therapy, valacyclovir, famciclovir, herpes zoster vaccine, herpes zoster prevention, immunocompromised patients, analgesia, infection control
MeSH terms
Valacyclovir, Famciclovir, Acyclovir, Adult, Aged, Aged, 80 and over, Analgesics, Antiviral Agents, Female, Herpes Zoster, Humans, Lidocaine, Male, Middle Aged, Retrospective Studies, Risk Factors, United States, Valine, Herpesvirus 3, Human, 2-Aminopurine, Cohort Studies, Incidence, Practice Guidelines as Topic, Neuralgia, Postherpetic, Herpes Zoster Vaccine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review